Luye / HEUFT: a milestone for safe pharmaceutical products

HEUFT Systems Technology (Shanghai) Co. Ltd. concluded a strategic cooperation agreement with one of the leading pharmaceuticals producers of the People’s Republic of China in good time before the beginning of the Chinese New Year: superior HEUFT systems will soon be taking over the comprehensive quality inspection of sensitive medicinal products on three of the Luye Pharma Group Ltd. lines.

The ceremonial signing of the contract by Li ShiXu, Vice General Manager of Shangdong Luye Pharmaceutical Co. Ltd. and Jürgen Kurz, Managing Director of HEUFT China is a significant milestone for the technology leader in in-line quality assurance for product and packaging regarding the expansion of its pharmaceutical business. One of the most important industry representatives in China now also relies on the unique solutions of the German manufacturer along with numerous other well-known drug manufacturers all over the world.

Luye, the pharmaceutical giant with a large product portfolio and a great deal of development power in areas such as oncology and cardiovascular diseases, is thus strengthening its operational reliability as well patient safety. And that is top priority for the manufacturer of sensitive medicinal products.

The wide variety of HEUFT technologies provides the pharmaceutical industry with many core advantages in this respect:

  • minimal footprint and greatest flexibility when implementing specific customer requirements

  • minimal maintenance costs and long-term reliability by doing without change parts subject to wear

  • in-house developed pulsed X-ray technology for the unrivalled careful and precise identification of optically invisible high-density foreign objects

  • highly safe technological environment and top product quality due to state-of-the-art camera systems and in-house developed software

The milestone agreement is a further step towards consolidating superior HEUFT inspection systems and extensive support by a powerful  team in the international pharma market.